ADL Amdl,

AMDL Announces ISO 13485 Audit Complete; Important Certification to Facilitate International Marketing of DR-70(R) Expected Soon TUSTIN, Calif., Dec. 10 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL; Berlin, Frankfurt), developer and marketer of tests for the early detection of cancer and other serious diseases, today said that it has successfully undergone an extensive audit to receive certification for EN ISO 13485 and Canadian Medical Device Regulations (CMDR). The Company expects to receive the certificate in approximately two weeks. "This is significant for AMDL since ISO 13485 certification is becoming the global standard for quality systems in the Medical Device and Diagnostic Industry," said Gary L. Dreher, AMDL President. "Canada requires CMDR certification and the European Union requires EN 13485 certification, while other nations are moving to require the same certification before allowing products to be marketed in their countries." The audit was conducted by TUV Rhineland of North America, which performs registration audits for ISO 13485 certification and the Canadian Medical Device Conformity System certification. "This is an important step forward for AMDL to ensure international sales of our test kit and is another critical milestone in our goal to globalize the marketing of DR-70(R)," Mr. Dreher said. About AMDL AMDL, Inc. (AMEX:ADL), headquartered in Tustin, California, is a theranostics company, involved in the detection and treatment of the same disease, cancer. AMDL is the inventor, developer and worldwide marketer through exclusive distribution agreements of the DR-70(R) non-invasive cancer blood test, which has demonstrated its ability to detect the presence in humans of up to 13 cancers 84 percent of the time overall. In a study published in the Journal of Immunoassay (1998, vol. 19, pp 63-72) DR-70(R) was shown to detect at least 13 different types of cancer (lung, breast, stomach, liver, colon, rectal, ovarian, esophageal, cervical, trophoblastic, thyroid, malignant lymphoma, pancreatic) although the sample size for 9 of the cancers was not statistically significant. Clinical trials of DR-70(R) have been conducted in Canada, China, Germany, Taiwan and Turkey. DR-70(R) can detect many kinds of cancer using a single tube of blood, eliminating the need for costly, multiple tests. AMDL also owns a combination immunogene therapy technology that is a possible treatment for those already diagnosed with cancer and could eventually be used as a vaccine to protect patients known to be at risk because of a family history for certain types of cancer. The combination therapy both builds the body's immune system and destroys cancer cells. More information about AMDL and its additional products can be obtained at http://www.amdlcorporate.com/ . Forward-Looking Statements Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's partners that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release. DATASOURCE: AMDL, Inc. CONTACT: Gary L. Dreher, President & CEO of AMDL, Inc., +1-714-505-4460 Web site: http://www.amdlcorporate.com/

Copyright